Obsidian Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $160M
Overview
Developing controllable cell therapies for cancer using a tunable protein-regulation platform.
Oncology
Technology Platform
The cytoDRiVE® platform uses small-molecule-regulated proteins to enable precise, tunable control of therapeutic protein expression in engineered cell therapies.
Funding History
1Total raised:$160M
Series C$160M
Opportunities
Potential to unlock cell therapy for solid tumors and improve the therapeutic window in hematologic cancers.
Risk Factors
Clinical validation of the control mechanism and complexity of manufacturing regulated cell products.
Competitive Landscape
Competes with other next-gen cell therapy firms like Lyell Immunopharma and Instil Bio, as well as companies developing CAR-T safety switches.